Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and the use of such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.

Abstract: A mounting assembly secures an electronic control unit upon a vehicle. The mounting assembly includes a bracket which can be attached to the vehicle's frame. The electronic control unit can be supported by the bracket. In one embodiment, a sleeve can be secured to the bracket and the electronic control unit can be at least partially disposed within a receptacle in the sleeve. In another embodiment, a guard can be secured to the sleeve.

Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Abstract: A system that incorporates teachings of the present disclosure may include, for example, an apparatus for testing having a controller to perform test case conflict resolution by comparing an execution descriptor to one or more platform descriptors. The execution descriptor can have one or more platforms to be tested, each platform comprising at least one among one or more bases, one or more modules, and combinations thereof. Each of the one or more platform descriptors can have one or more test cases and a description of one or more platform limitations for executing the one or more test cases. Additional embodiments are disclosed.

Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Abstract: Atomic testing of a multiplicity of scenarios includes generating a listing of interacting scenarios which are likely to cause a failure, and testing ones of the scenarios not included in the listing according to a binary search strategy to identify a subset of the scenarios as a source of failure among the scenarios. Additionally, the listing can be updated with newly identified interacting scenarios which are likely to cause a failure.

Abstract: The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: The present invention discloses novel compounds of Formula (I), or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Abstract: The present invention discloses novel compounds of Formula I, or pharmaceutically acceptable salts thereof, which have glucagon receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I as well as methods of using them to treat diabetic and other glucagon related metabolic disorders, and the like.

Abstract: The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods and intermediates for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I) pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Abstract: A method for efficiently stress testing a service oriented architecture based application. A business process flow is recorded between a client and a server. When an XML document is extracted from the recorded business process flow, an XML document file is created for the extracted XML document, an XML document descriptor file is created comprising XPath queries for data elements in the XML document file, a configuration file is created comprising user input parameters obtained from the recorded business process flow, and test input data file is created. The user input parameters in the configuration file are used to generate a test script to test the service oriented architecture based application, wherein data values from the test input data file are inserted into a template of the XML document file at locations specified by the XPath queries in the XML document descriptor file. The test script is then executed.

Abstract: The present invention relates to novel substituted imidazo[1,2-b]pyridazine compounds of Formula (I): pharmaceutical compositions thereof, and the use such compounds as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric disorders and neurological diseases.

Abstract: The present invention discloses novel substituted aryl alkylamine compounds of Formula (I) or pharmaceutically acceptable salts thereof which have selective histamine-H3 receptor antagonist activity as well as methods for preparing such compounds.

Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.

Abstract: The present invention relates to a melanin concentrating hormone antagonist compound of formula I: (I); or a pharmaceutically acceptable salt, solvate, enantiomer or prodrug thereof useful in the treatment, prevention or amelioration of symptoms associated with obesity and related diseases.

Abstract: The present invention provides antitumor compounds of the formula (I), and antitumor methods

Abstract: The present invention provides antineoplastic compounds of the formula: and antineoplastic methods.

Abstract: Sound recordings are played through a closely-spaced pair of loudspeakers with a predetermined listener position having an included angle of between 6° and 20°, and filter means being employed in creating said sound recordings, the filter means having characteristics such that when the sound recordings are played, the need to provide a virtual imaging filter means at the inputs to the loudspeakers to create virtual sound sources is avoided, the sound recording being such that when played through the loudspeakers a phase difference between vibrations of the two loudspeakers results where the phase difference varies with frequency from low frequencies where the vibrations are substantially out of phase to high frequencies where the vibrations are in phase, the lowest frequency at which the vibrations are in phase being determined approximately by a ringing frequency, f0.